Effects of ipragliflozin on skeletal muscle adiposity in patients with diabetes and metabolic dysfunction-associated steatotic liver disease.
Ishimaru Y, Kessoku T, Nonaka M, Kitajima Y, Hyogo H, Nakajima T, Imajo K, Kubotsu Y, Isoda H, Kawanaka M, Yoneda M, Anzai K, Nakajima A, Furukawa K, Kawaguchi A, Takahashi H.
Ishimaru Y, et al. Among authors: anzai k.
Intern Med. 2024 Nov 1. doi: 10.2169/internalmedicine.4456-24. Online ahead of print.
Intern Med. 2024.
PMID: 39496446
Free article.